Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Common Equity: 2022-2025

Historic Common Equity for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to $71.8 million.

  • Corvus Pharmaceuticals' Common Equity rose 478.35% to $71.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.8 million, marking a year-over-year increase of 478.35%. This contributed to the annual value of $32.6 million for FY2024, which is 15.81% down from last year.
  • As of Q3 2025, Corvus Pharmaceuticals' Common Equity stood at $71.8 million, which was down 10.54% from $80.2 million recorded in Q2 2025.
  • Over the past 5 years, Corvus Pharmaceuticals' Common Equity peaked at $89.7 million during Q1 2022, and registered a low of $12.4 million during Q3 2024.
  • Moreover, its 3-year median value for Common Equity was $48.9 million (2023), whereas its average is $46.6 million.
  • As far as peak fluctuations go, Corvus Pharmaceuticals' Common Equity plummeted by 71.98% in 2024, and later soared by 478.35% in 2025.
  • Corvus Pharmaceuticals' Common Equity (Quarterly) stood at $56.1 million in 2022, then plummeted by 31.06% to $38.7 million in 2023, then decreased by 15.81% to $32.6 million in 2024, then spiked by 478.35% to $71.8 million in 2025.
  • Its Common Equity was $71.8 million in Q3 2025, compared to $80.2 million in Q2 2025 and $49.3 million in Q1 2025.